Fresh off its filing for a new COPD drug, Massachusetts-based Sunovion Pharmaceuticals struck a $642 million deal to acquire Toronto-based Cynapsus Therapeutics and its Parkinson’s disease drug candidate.
The U.S. Food and Drug Administration strengthened warnings about the danger of combining opioid painkillers or cough medicines containing opioids with benzodiazepines, a common class of sedatives.
Novartis AG is dissolving its Cell and Gene Therapy Unit, according to Endpoints News, citing a note sent to 400 employees by division president Usman Azam.
Embattled Theranos has run into another testing snag, this time with its proposed blood test for the Zika virus. The company was forced to withdraw its request for emergency clearance of the test after inspectors with the U.S. Food and Drug Administration found the company did not include proper patient protections in its study, according to the Wall Street Journal.
Medivir AB announced that it plans to split up into two independent companies.
Express Scripts Holding, the largest U.S. pharmacy benefit manager, said it will implement a program in 2017 that guarantees per-patient spending caps on diabetes drug costs in an effort to limit soaring increases for its customers.
University of Michigan researchers said their own experiments undermine recent allegations of security flaws in St. Jude Medical Inc.’s pacemakers and other implantable medical devices.
The U.S. Food and Drug Administration approved Novartis AG’s biosimilar version of Amgen Inc.’s arthritis drug Enbrel.
A White Paper from the Community Oncology Alliance (COA) looks at recent moves by Pharmacy Benefit Managers (PBMs) to increase corporate profits by declaring all physician dispensing to be out-of-network.
A California startup has developed a portable technology that will allow consumers to test their food for gluten on the go.
Child malnutrition cost the Philippines $7 billion or nearly 3 percent of its GDP in one year in terms of education spending and lost productivity, while hunger-related stunting is on the rise among children, a global aid agency said.
Rigel Pharmaceuticals Inc. said its experimental drug to treat a bleeding disorder met its main goal in the first of two late-stage trials.
Carmat’s shares jumped after the French company announced the first implantation of its bioprosthetic artificial heart in a final-stage clinical trial.
Key Parkinson’s Trial Delayed Due to Feud Between a Georgetown University Scientist and The Michael J. Fox Foundation
In late 2015, Charbel Moussa, a researcher at Georgetown University Medical Center (GUMC) in Washington, announced the results of a promising Phase I clinical trial of cancer drug nilotinib in Parkinson’s disease. A second clinical trial was expected to start in October, but is currently being delayed due to a what is being dubbed a “feud” between Moussa, Georgetown, and the Michael J. Fox Foundation.
Contract research organization Albany Molecular Research (AMRI), headquartered in Albany, New York, announced that it will be restructuring specific operations in the U.S. and Europe. An unspecified number of jobs will be cut as a result.
Drugmaker Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a late-stage trial to determine its ability to treat COPD.
Valeant Pharmaceuticals International Inc. was sued by buyers of its drugs, who accused the Canadian company of racketeering by forcing them to pay exorbitant prices.
New Jersey researchers said they had identified perhaps the first strain of E. Coli bacteria in the United States with mobile genes that make it resistant to two types of antibiotics now considered last-line defenses against superbugs.
Mylan NV said it would launch the first generic version of its allergy auto-injector EpiPen at half the price of the branded product, the drugmaker’s second step in less than a week to counter a wave of criticism over the product’s high price.
The spread of the Zika virus across tropical Southeast Asia is likely to be significantly under-reported as local health authorities fail to conduct adequate screening, regional experts said.